# Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

> **NCT05638620** · PHASE1 · COMPLETED · sponsor: **Jonathann Kuo, MD** · enrollment: 20 (actual)

## Conditions studied

- Post Acute COVID-19 Syndrome
- Long COVID
- Long Covid19
- COVID-19 Recurrent
- Post-Acute COVID-19
- Post-Acute COVID-19 Infection
- SARS-CoV2 Infection
- Post Acute Sequelae of COVID-19
- Dysautonomia
- Dysautonomia Like Disorder
- Dysautonomia Orthostatic Hypotension Syndrome
- Post COVID-19 Condition
- Post-COVID Syndrome
- Post COVID-19 Condition, Unspecified
- Post-COVID-19 Syndrome

## Interventions

- **DRUG:** stellate ganglion block with 0.5% bupivacaine

## Key facts

- **NCT ID:** NCT05638620
- **Lead sponsor:** Jonathann Kuo, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-03
- **Primary completion:** 2023-06-15
- **Final completion:** 2023-12-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05638620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05638620, "Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05638620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*